Allotment

Accretion Pharmaceuticals launched a book-built IPO worth ₹29.75 crore, consisting entirely of a fresh issue of 0.29 crore shares.
The IPO opened for bidding on May 14, 2025, and closed on May 16, 2025. The allotment was finalized on May 19, 2025, and the shares were subsequently listed on NSE SME on May 21, 2025.
The price band for the IPO was fixed at ₹101 per share. The lot size for an application is 1,200 shares. For retail investors, the minimum investment is 1 lot (1,200 shares), amounting to ₹1,21,200 (based on the upper price). HNI investors must subscribe to a minimum of 2 lots (2,400 shares), totaling ₹2,42,400.
The IPO was managed by Jawa Capital Services Pvt. Ltd. as the Book Running Lead Manager, with Kfin Technologies Ltd. serving as the Registrar of the Issue. Gretex Share Broking Pvt. Ltd. acted as the market maker for the IPO.
Investors can bid for a minimum of 1,200 shares, with additional bids required in multiples of 1,200 shares.
₹1010%
Open
HIgh - Low
Previous Close
Total Traded Value
52 Weeks High
52 Weeks Low
Updates On
IPO. Open
IPO. Close
IPO. Price
IPO Market price
| IPO Date | 21 May |
| IPO Listing Date | 21 May |
| IPO Face Value | ₹10 per share |
| IPO Price Range | ₹101.00 |
| IPO Issue Size | 29,46,000 shares |
| IPO Sale Type | Fresh Capital |
| Employee Discount | - |
| IPO Issue Type | Bookbuilding IPO |
| IPO Listing | NSE SME Platform |
| hare Holding Pre Issue | 81,70,000 shares |
| IPO Open Date | 14 May |
| IPO Close Date | 16 May |
| IPO Allotment (Tentative) | 19 May |
| Refunds | 20 May |
| Credit to Demat Account | 20 May |
| IPO Listing Date | 21 May |
| Category | Offer |
|---|---|
| QIB Shares Offered | 3,52,800 Shares |
| NII (HNI) Shares Offered | 12,22,800 Shares |
| Retail Shares Offered | 12,22,800 Shares |
Investors can bid for a minimum of 1,200 shares, with additional bids required in multiples of 1,200 shares.
| Application | Lots | Share | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1,200 | ₹1,21,200 |
| Retail (Max) | 1 | 1,200 | ₹1,21,200 |
| S-HNI (Min) | 2 | 2,400 | ₹2,42,400 |
| S-HNI (Max) | - | - | - |
| B-HNI (Min) | - | - | - |
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical manufacturing company engaged in the production and sale of tablets, capsules, and a wide range of healthcare products. The company also provides contract manufacturing services, catering to domestic and international markets.
Manufacturing and Certifications:
The company’s manufacturing facility is located in Ahmedabad (Sanand), Gujarat, and is supported by internationally recognized quality standards. Accretion Pharmaceuticals holds ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 certifications, demonstrating its commitment to quality assurance, food safety, and environmental management systems.
Product Portfolio and Services:
Accretion Pharmaceuticals manufactures and markets a diverse range of formulations, including:
Tablets and Capsules – Covering antibiotics, anti-inflammatory drugs, pain management, cardiovascular, and gastrointestinal medicines.
Oral Liquids and Syrups – Used in respiratory, pediatric, and digestive treatments.
External Preparations – Including ointments, creams, gels, lotions, medicated shampoos, mouthwashes, and dusting powders for dermatological care.
Oral Powders – Such as sachets and dry syrups.
Ayurvedic and Herbal Products – Focused on natural wellness solutions for immunity, digestion, and overall health.
Global Presence:
The company has expanded its international footprint, with operations in more than 20 countries, including regions across Africa, Southeast Asia, and the Middle East.
Workforce:
As of January 2025, Accretion Pharmaceuticals employed 83 personnel, including 4 Executive Directors.
Competitive Strengths:
Experienced promoters and a capable management team
Long-standing relationships with clients and suppliers
Strong focus on delivering high-quality pharmaceutical products
Well-established supply chain and customer relationships, fostering trust and goodwill
| Assets | 39.99 | 27.05 | 20.58 |
| Total Income | 35.75 | 33.94 | 29.53 |
| Profit After Tax | 5.24 | 3.88 | 0.1 |
| EBITDA | - | - | - |
| NET Worth | 13.58 | 5.35 | 3.84 |
| Reserves and Surplus | 5.41 | 1.35 | - |
| Total Borrowing | 13.79 | 13.48 | 8.47 |
| ROE | 72.47% |
| ROCE | 36.73% |
| Debt/Equity | 2.52 |
| RoNW | 72.47% |
| PAT Margin | 11.51% |
| EBITDA Margin | - |
| Price to Book Value | 7.55 |
IPO Objects of the Issue
| S.No. | Objects of the ipo Resources Detail | IPO Amount |
|---|---|---|
| 1 | Funding capital expenditure requirements for the purchase of equipment/machineries | 2.7 |
| 2 | To meet out the expenses of Working Capital Requirement | 14.68 |
| 3 | To meet out the General Corporate Purposes; | 4.43 |
| 4 | Offer for Sale (OFS) | - |
Accretion Pharmaceuticals Ltd. Address
29 Xcelon Ind Park 1,
B/h, Intas Pharmaceuticals, Vasna Chacharvad
Sanand,
Ahmedabad, Gujarat, 382213
+91-97148 82929
compliance@accretionpharma.com
IPO Registrar
Kfin Technologies Ltd.
04067162222, 04079611000
apl.ipo@kfintech.com
https://ipostatus.kfintech.com/